Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.39 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.39 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.39 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.39 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.39 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.39 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25504216 | 0.86 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2TUBB4A | |
| SCHEMBL1888479 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2TUBB4A | |
| SCHEMBL1888482 | 0.80 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2TUBB4A | |
| SCHEMBL19131836 | 0.76 | ALDH1A1 (0.42) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL8256698 | 0.75 | SLC9A1 (0.50) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C | |
| SCHEMBL31289323 | 0.75 | SLC9A1 (0.50) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C | |
| SCHEMBL13173782 | 0.74 | KDM1A (0.44) | ALDH1A1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL13488484 | 0.74 | FAAH (0.39) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2TUBB4A | |
| SCHEMBL24983450 | 0.74 | SLC9A1 (0.40) | FAAHMGLLSLC9A1 | |
| SCHEMBL13057368 | 0.73 | CYP1A2 (0.40) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11788080-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230321109-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACROLIDE DIASTEREOMERS, METHODS OF THEIR SYNTHESIS AND THERAPEUTIC USES | REGENERON PHARMA (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321109-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACROLIDE DIASTEREOMERS, METHODS OF THEIR SYNTHESIS AND THERAPEUTIC USES | REGENERON PHARMA (US) | 2023-10-12 | — | — | US | disclosed |
| US-11708381-B2 | Inhibitors of androgen receptor signaling | XAVIER UNIVERSITY OF LOUISIANA (US) | 2023-07-25 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11661437-B2 | Steroid derivative regulators, method for preparing the same, and uses thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-11661437-B2 | Steroid derivative regulators, method for preparing the same, and uses thereof | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9604930-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160354482-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACROLIDE DIASTEREOMERS, METHODS OF THEIR SYNTHESIS AND THERAPEUTIC USES | REGENERON PHARMACEUTICALS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20090317326-A1 | RADIOFLUORINATION METHODS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-24 | — | — | US | disclosed |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | WYETH (US) | 2009-11-26 | — | — | US | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| US-20070161578-A1 | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | SCHERING CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | ALDH1A1 3598/4885CYP1A2 4509/4885CYP2C19 4349/4885 |
| US-20160354482-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACROLIDE DIASTEREOMERS, METHODS OF THEIR SYNTHESIS AND THERAPEUTIC USES | CD22, HDAC6, NR1H4 | ALDH1A1 2832/4885CYP1A2 868/4885CYP2C19 761/4885 |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | ALDH1A1 3184/4885CYP1A2 1023/4885CYP2C19 1435/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ALDH1A1 2151/4885CYP1A2 3086/4885CYP2C19 3490/4885 |
| US-11708381-B2 | Inhibitors of androgen receptor signaling | AR, ESRRA, ESRRB | ALDH1A1 2589/4885CYP1A2 4177/4885CYP2C19 4749/4885 |
| US-11661437-B2 | Steroid derivative regulators, method for preparing the same, and uses thereof | GABRR1, GABRB1, GABRD | ALDH1A1 1040/4885CYP1A2 243/4885CYP2C19 192/4885 |
| US-20230321109-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACROLIDE DIASTEREOMERS, METHODS OF THEIR SYNTHESIS AND THERAPEUTIC USES | CD22, HDAC6, NR1H4 | ALDH1A1 2832/4885CYP1A2 868/4885CYP2C19 761/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | ALDH1A1 3598/4885CYP1A2 4509/4885CYP2C19 4349/4885 |
| US-20070161578-A1 | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | NR1H4, NR1H3, NR1H2 | ALDH1A1 2512/4885CYP1A2 1440/4885CYP2C19 3610/4885 |
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | ALDH1A1 1333/4885CYP1A2 492/4885CYP2C19 628/4885 |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GK, GCK | ALDH1A1 612/4885CYP1A2 1007/4885CYP2C19 213/4885 |
| US-20090317326-A1 | RADIOFLUORINATION METHODS | CDC73, TMEM14C, FLI1 | ALDH1A1 382/4885CYP1A2 353/4885CYP2C19 926/4885 |
| US-20090291971-A1 | HETEROARYL ETHERS AND PROCESSES FOR THEIR PREPARATION | AHR, MALT1, ABL1 | ALDH1A1 1591/4885CYP1A2 38/4885CYP2C19 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.